What is Transitional Cell Carcinoma with Adenocarcinomatous Differentiation of the Ureter?
Transitional cell carcinoma with adenocarcinomatous differentiation of the ureter is a rare type of urothelial carcinoma that displays characteristics of both transitional cell carcinoma and adenocarcinoma. This unique type of cancer begins in the cells lining the ureter and shows glandular cell features characteristic of adenocarcinomas.
Transitional Cell Carcinoma is the most common type of cancer in the urinary tract, including the ureters. Transitional Cell Carcinoma originates in the urothelium, which is a layer of transitional cells that line the inside of the bladder, ureters, and parts of the kidneys. These cells are named ‘transitional’ because of their ability to change shape and stretch when the bladder is full.
In some cases, Transitional Cell Carcinoma can show features of another type of cancer called adenocarcinoma. Adenocarcinomas originate from glandular cells, which are found in various organs and produce fluids or mucus. When Transitional Cell Carcinoma shows features of adenocarcinoma, it is said to have ‘adenocarcinomatous differentiation’.
Symptoms of transitional cell carcinoma with adenocarcinomatous differentiation may include:
- Blood in the urine (hematuria)
- Flank pain or lower abdominal pain
- Frequent urination or a persistent urge to urinate
- Unexplained weight loss
- Generalised fatigue
Disease Aetiology (Causes)
The precise cause of this cancer is unknown, but it’s likely linked to chronic irritation or inflammation of the urinary tract. Potential risk factors include smoking, exposure to certain industrial chemicals, and a history of recurrent urinary tract infections.
The diagnosis of transitional cell carcinoma with adenocarcinomatous differentiation typically involves:
- Detailed medical history and physical examination
- Urine tests to check for blood or signs of infection
- Imaging tests such as a CT scan, MRI or ultrasound to identify the presence and extent of the tumour
- Biopsy and histopathological examination to confirm the diagnosis
The treatment for transitional cell carcinoma with adenocarcinomatous differentiation of the ureter often involves:
- Surgery: The primary treatment, usually involving removal of the affected ureter and the kidney on the same side (nephroureterectomy).
- Chemotherapy: May be used before (neoadjuvant) or after (adjuvant) surgery to reduce the risk of recurrence and improve survival.
What Support can we Give for Transitional Cell Carcinoma with Adenocarcinomatous Differentiation of the Ureter?
Transitional Cell Carcinoma with Adenocarcinomatous Differentiation of the Ureter is rare cancer, meaning it is not as well known as other forms of cancer. Without a Ribbon is an Australian organisation that provides support for individuals who suffer from rare cancers. So, we provide a designated platform for Warriors to obtain information specific to their Rare Cancer. We also provide annual opportunities for our Warriors to meet and learn from each other. If you suffer from rare cancer such as Transitional Cell Carcinoma with Adenocarcinomatous Differentiation of the Ureter, we can help and support you through your journey thanks to the generous donations we receive. Click the link below to sign up and become a Warrior today!
You can help us with your donation:
Without a Ribbon is a charity that works hard to aid those who suffer from rare cancers. You can help our cause in a variety of ways: